Comparative analysis of pharmacokinetic parameters, bioequivalence, safety, tolerability and immunogenicity of semaglutide-based drug for the treatment of obesity

Comparative analysis of pharmacokinetic parameters, bioequivalence, safety, tolerability and immunogenicity of semaglutide-based drug for the treatment of obesity

One of the new classes of drugs for weight loss in overweight and obesity, the safety and efficacy of which have been proven in large-scale studies, are glucagon-like peptide-1 receptor agonists (GLP-1 agonists). Separately, it is worth highlighting the main representative from the GLP-1 agonists cl...

Full description

Saved in:
Bibliographic Details
Main Authors: A. S. Ametov, P. A. Bely, K. Y. Zaslavskaya, E. A. Rogozhina, V. S. Shcherbakova, Y. G. Kazaishvili, A. V. Taganov, T. G. Bodrova, E. S. Mishchenko, K. N. Koryanova, L. I. Shcherbakova
Format: Article
Language:Russian
Published: Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute 2025-03-01
Series:Фармация и фармакология (Пятигорск)
Subjects:
semaglutide
glucagon-like peptide-1 receptor agonist
obesity
subcutaneous administration
safety
tolerability
immunogenicity
pharmacokinetic parameters
Online Access:https://www.pharmpharm.ru/jour/article/view/1613
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.pharmpharm.ru/jour/article/view/1613

Similar Items